Summit Therapeutics Inc. (SMMT)

Market Cap	14.26B +5.4%
Revenue (ttm)	n/a
Net Income	-832.68M
EPS	-1.07
Shares Out	799.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,506,291
Open	17.77
Previous Close	17.84
Day's Range	17.38 - 18.14
52-Week Range	12.07 - 29.23
Beta	-1.52
Analysts	Buy
Price Target	29.90 (+67.7%)
Earnings Date	Nov 4, 2026

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 265
• Stock Exchange: Nasdaq
• Ticker Symbol: SMMT
• Website: https://www.smmttx.com

Analyst Summary

According to 17 analysts, the average rating for SMMT stock is "Buy." The 12-month stock price target is $29.9, which is an increase of 67.70% from the latest price.

Price Target

$29.9

(67.70% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 11, 2026

Data Sources Report a data error